CurrentCentenePolicy CP MP.153

Helicobacter Pylori Serology Testing

Defines Centene-affiliated health plan coverage stance and clinical rationale for H. pylori serologic testing for diagnosis and test-of-cure; affects providers ordering H. pylori diagnostic tests for plan members.

Policy Summary

PayerCentene

PolicyHelicobacter Pylori Serology Testing

Policy CodePolicy CP MP.153

Change TypeNo material change

Effective Date

Next Review Date

Key ActionUse urea breath test or stool antigen testing (preferred) instead of serology for diagnosing active H. pylori infection and for test-of-cure.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

not medically necessarycoverage stance for H. pylori serology

4–6 weeksUBT test-of-cure timing

88%–95% / 95%–100%UBT performance (sens/spec)

stool antigen or UBTpreferred noninvasive tests

Coverage Criteria — H. pylori Serology

Not Medically Necessary: H. pylori Serology for Diagnosis or Test-of-Cure

Not medically necessary — serology is excluded for diagnosis of active H. pylori infection and for confirming eradication (test-of-cure). Use alternative tests to detect active infection and to document cure.

Primary policy: H. pylori serology testing is not medically necessary for diagnosing H. pylori infection or for evaluating treatment effectiveness (test-of-cure).

Serology detects IgG and cannot distinguish active from past infection; it cannot be used to confirm eradication. Use urea breath test (UBT) or stool antigen testing to detect active infection and to document cure.

Serologic (antibody) testing for Helicobacter pylori is excluded for the purpose of diagnosing active infection and for confirming eradication (test-of-cure). Antibody assays detect prior exposure and cannot reliably distinguish active from past infection, and therefore are not appropriate for diagnostic or test-of-cure use.

H. pylori serology testing is considered not medically necessary for diagnosing H. pylori infection or for evaluating treatment effectiveness. Providers should use tests that detect active infection (for example, urea breath tests or stool antigen tests) when diagnosis or test-of-cure documentation is required.

Policy Summary

PayerCentene

PolicyHelicobacter Pylori Serology Testing

Policy CodePolicy CP MP.153

Change TypeNo material change

Effective Date

Next Review Date

Key ActionUse urea breath test or stool antigen testing (preferred) instead of serology for diagnosing active H. pylori infection and for test-of-cure.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions, Documentation, and Billing Guidance

Note

Coding guidance (informational) — coding references do not guarantee payment

Coding references in this policy are informational only. Inclusion or omission of specific CPT/HCPCS/ICD-10 codes does not guarantee coverage or payment. Providers must reference current coding manuals and payer billing guidance and verify benefit coverage prior to claim submission.

Providers should consult up-to-date professional coding guidance before submitting claims.
Inclusion/exclusion of codes in this policy is not a guarantee of payment.

Denial Risk

Denial risk for serology testing

Serologic (antibody) testing cannot distinguish active H. pylori infection from past exposure and is not recommended for diagnosing active infection or for confirming eradication. Claims for serology testing to diagnose H. pylori infection or to document cure are at risk for denial under this policy.

Serology claims (antibody tests) for diagnosing active H. pylori infection are subject to denial.
Serology is not acceptable for test-of-cure purposes.

Note

Preferred testing sequence — UBT or stool antigen preferred over serology

Urea breath tests (UBT) or stool antigen tests using validated monoclonal assays are the preferred noninvasive tests to diagnose active H. pylori infection and to document eradication after therapy. UBT and stool antigen detect active infection; serology does not.

Preferred diagnostic tests: Urea breath test (UBT) or stool antigen test (validated monoclonal).
Serology is not preferred for diagnosing active infection.

Documentation Required

Test-of-cure documentation — use UBT or stool antigen after treatment

For patients with prior eradication therapy or a history of peptic ulcer disease, document test-of-cure using urea breath testing or stool antigen testing performed ≥4–6 weeks after completion of eradication therapy. Ensure proton pump inhibitors (PPIs) are discontinued at least 2 weeks before testing when possible to optimize accuracy.

Test-of-cure methods: UBT or stool antigen.
Timing: Perform test-of-cure ≥4–6 weeks after completion of eradication therapy.
Medication precautions: Stop PPIs ≥2 weeks before testing when clinically feasible.

Definitions of Tests

inv-13: Urea breath test — definition and performance

DefinitionUrea breath test (UBT): a noninvasive test that requires ingestion of urea labeled with carbon-13 or carbon-14 to detect active H. pylori infection

PerformanceSensitivity ~88%–95% and specificity ~95%–100% for detection of active H. pylori infection

Use as test-of-cureUBT is the noninvasive test of choice and can be used to confirm eradication following therapy

inv-14: Stool antigen test — definition and test-of-cure use

DefinitionStool antigen test: a noninvasive assay (typically monoclonal antibody–based) that detects active H. pylori infection in feces

Use as test-of-cureCan be used to confirm eradication (test-of-cure) and is as accurate as UBT when a validated laboratory-based monoclonal test is used

PPI considerationPPIs should be stopped for 2 weeks before stool antigen testing, though stool tests are less affected by PPIs than UBT

inv-15: Serology — definition and limitation

DefinitionSerology (antibody testing): detects IgG antibodies to H. pylori in serum, usually by ELISA

LimitationCannot distinguish active infection from past infection and therefore is not appropriate for confirming eradication (not a test-of-cure)

Clinical implicationSerologic tests are convenient but less accurate than UBT or stool antigen tests for detecting active infection

OpenPayer

Helicobacter Pylori Serology Testing

Coverage Criteria — H. pylori Serology

Coding References and Test Timing

Provider Actions, Documentation, and Billing Guidance

Background

Definitions of Tests